MARÍA
NÚÑEZ NÚÑEZ
DOCENTE INVITADA
Publications (27) MARÍA NÚÑEZ NÚÑEZ publications
2024
-
Post-publication research integrity concerns in randomized clinical trials: A scoping review of the literature
International Journal of Gynecology and Obstetrics, Vol. 166, Núm. 3, pp. 984-993
2023
-
Assessing the Integrity of Clinical Trials Included in Evidence Syntheses
International Journal of Environmental Research and Public Health, Vol. 20, Núm. 12
-
Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety
Frontiers in Pharmacology, Vol. 14
-
International multi-stakeholder consensus statement on clinical trial integrity
BJOG: An International Journal of Obstetrics and Gynaecology, Vol. 130, Núm. 9, pp. 1096-1111
-
Research integrity in randomized clinical trials: A scoping umbrella review
International Journal of Gynecology and Obstetrics, Vol. 162, Núm. 3, pp. 860-876
2022
-
Compatibility of prolonged infusion antibiotics during Y-site administration
Nursing in Critical Care, Vol. 27, Núm. 6, pp. 849-858
-
Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19
Frontiers in Immunology, Vol. 13
-
Predictors of inappropriate antimicrobial prescription: Eight-year point prevalence surveys experience in a third level hospital in Spain
Frontiers in Pharmacology, Vol. 13
-
Research integrity in clinical trials: innocent errors and spin versus scientific misconduct
Current Opinion in Obstetrics and Gynecology, Vol. 34, Núm. 5, pp. 332-339
-
Second Victim Support at the Core of Severe Adverse Event Investigation
International journal of environmental research and public health, Vol. 19, Núm. 24
2021
-
Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation
Medicina Clinica, Vol. 156, Núm. 12, pp. 602-605
2020
-
Author Correction: A nonlinear time-series analysis approach to identify thresholds in associations between population antibiotic use and rates of resistance (Nature Microbiology, (2019), 4, 7, (1160-1172), 10.1038/s41564-019-0410-0)
Nature Microbiology
-
Dalbavancin is a novel antimicrobial against Gram-positive pathogens: Clinical experience beyond labelled indications
European Journal of Hospital Pharmacy, Vol. 27, Núm. 5, pp. 310-312
-
Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill
Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 2, pp. 429-433
-
Randomized, double-blind, controlled trial, phase III, to evaluate the use of platelet-rich plasma versus hyaluronic acid in hip coxarthrosis
Revista Espanola de Cirugia Ortopedica y Traumatologia, Vol. 64, Núm. 2, pp. 134-142
-
Uso de dalbavancina en pacientes en hemodiálisis con infecciones protésicas endovasculares por microorganismos multirresistente.
Diálisis y trasplante: publicación oficial de la Sociedad Española de Diálisis y Trasplante, Vol. 41, Núm. 2, pp. 18-20
2019
-
A nonlinear time-series analysis approach to identify thresholds in associations between population antibiotic use and rates of resistance
Nature Microbiology, Vol. 4, Núm. 7, pp. 1160-1172
-
Indicators of the hospital use of antimicrobial agents based on consumption
Farmacia Hospitalaria, Vol. 43, Núm. 3, pp. 94-100
2018
-
Analysis of quality antimicrobial agent use in the emergency department of a tertiary care hospital
Emergencias, Vol. 30, Núm. 5, pp. 297-302
-
Potential interactions in a cohort of elderly HIV-positive patients
Farmacia Hospitalaria, Vol. 42, Núm. 4, pp. 163-167